Form 4: Sangamo Therapeutics Director Courtney Beers Reports Significant Equity Grants

Sangamo Therapeutics Director Courtney Beers has reported the acquisition of 25,000 restricted stock units and 50,000 stock options, increasing her beneficial ownership in the company.

Summary

• Courtney Beers, a Director of Sangamo Therapeutics, Inc. (SGMO), reported changes in her beneficial ownership of company securities.
• On June 12, 2025, Ms. Beers acquired 25,000 shares of common stock through a Restricted Stock Unit (RSU) grant, with a transaction price of $0.
• These 25,000 RSU shares are set to fully vest on the earlier of June 12, 2026, or the day prior to the 2026 annual meeting of stockholders, contingent on her continuous service.
• Following this transaction, Ms. Beers beneficially owns 82,650 shares of common stock, which includes 6,251 shares from a December 15, 2022 RSU grant that will vest on December 15, 2025.
• Additionally, on June 12, 2025, Ms. Beers acquired 50,000 stock options with an exercise price of $0.503 per share.
• These stock options are immediately exercisable, but any unvested shares purchased are subject to repurchase rights by the Issuer upon cessation of her continuous service.
• The 50,000 shares subject to the option will vest in 12 successive equal monthly installments following the grant date, also subject to continuous service.
• The stock options have an expiration date of June 11, 2035.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While a Form 4 primarily reports a transaction, the granting of equity to a director signifies continued alignment of interests between management and shareholders, which is generally viewed favorably. It does not, however, provide information on the company's operational or financial performance.

Positives

• The equity grants to Director Courtney Beers align her interests with those of the shareholders, as her compensation is tied to the company's future stock performance.
• The grants demonstrate the company's commitment to retaining and incentivizing key management and board members.

Risks

• The vesting of both the Restricted Stock Units (RSUs) and stock options is contingent upon the Reporting Person's 'Continuous Service' with the Issuer, meaning the grants could be forfeited if service ceases before vesting.
• Unvested shares purchased under the stock option are subject to certain repurchase rights by the Issuer upon cessation of continuous service, which could limit the immediate benefit to the Reporting Person.

Future Outlook

The equity grants indicate a forward-looking compensation structure, with vesting schedules extending into 2025 and 2026 for RSUs, and stock options expiring in 2035, tying the director's long-term incentives to the company's future performance.

Industry Context

This Form 4 filing is a standard disclosure for insider transactions, common across all publicly traded companies. It reflects a routine aspect of executive and director compensation in the biotechnology and pharmaceutical industries, where equity incentives are frequently used to align leadership interests with long-term company growth and shareholder value.

Corporate Governance

Related Party Transactions

• The reported acquisition of Restricted Stock Units (RSUs) and stock options by Director Courtney Beers constitutes a related party transaction, as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial incentives with shareholder interests, potentially encouraging decisions that enhance long-term stock value.
• Employees (specifically the Reporting Person): The grants represent a significant component of the director's compensation, contingent on continued service and company performance.

Next Steps

• The newly granted Restricted Stock Units (RSUs) will vest on the earlier of June 12, 2026, or the day prior to the 2026 annual meeting of stockholders, subject to continuous service.
• The 50,000 stock options will vest in 12 successive equal monthly installments following the grant date, subject to continuous service.
• The final installment of the December 15, 2022 RSU grant will vest on December 15, 2025.

Key Dates

Keywords

Sangamo Therapeutics, SGMO, Form 4, Insider Transaction, Equity Grant, Restricted Stock Unit, RSU, Stock Option, Director Compensation, Beneficial Ownership, SEC Filing